Opinion|Videos|June 27, 2024
Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Which patients are most suitable for a HER2-directed antibody-drug conjugate (ADC) in HR+/HER2-low metastatic breast cancer?
- Would you consider trastuzumab deruxtecan for second-line therapy or as a later line?
Advertisement
Related to this article
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5